CoChat
Sign Up
Cited by 377Antifungal resistance and susceptibilityFungal Infections and StudiesFungal Plant Pathogen Control

The DOI matches its Crossref record; 922 of the 930 references it cites were found in a registry or an index.

Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development

Groll, Andreas H., Piscitelli, Stephen C., Walsh, Thomas J.·1998·Advances in pharmacology
DOI 10.1016/s1054-3589(08)60129-5
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/s1054-3589(08)60129-5

Cites

922 of 922 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Items 801–922 of 922

Research works printed but not linked: 18

  1. Atkinson, 1969, Pharmacokinetics of intrathecal administered amphotericin B., Am. Rev. Respir. Dis., 99, 917
  2. Benhamu, 1991, Does ketoconazole prevent fungal infection in children treated with high-dose chemotherapy and bone-marrow transplantation?, Bone Marrow Transplant., 7, 127
  3. Bernardo, 1994, The effect of L-arginine on amphotericin B-induced nephrotoxicity., J. Am. Soc. Nephrol., 5, 917
  4. Brammer, 1987, A review of the pharmacokinetics of fluconazole (UK-49,858) in laboratory animals and man, 141
  5. Feldman, 1992, The use of granulocyte-stimulating factor (GCSF) enhanced granulocyte transfusions from normal donors in patients with neutropenia related fungal infections, Blood, 80, 414a
  6. G. Gaenger, G. Just-Nuebling, M. Eichel, R. Hoika, W. Stille (1993). Itraconazole solution in patients with non-response to fluconazole. In Abstracts of the IXth International Conference on AIDS, abstract 1394.
  7. Gascoigne, 1981, The kinetics of ketoconazole in animals and man., Clin. Res. Rev., 1, 177
  8. Gelfand, 1988, Amphotericin B treatment of human mononuclear cells in vitro results in secretion of tumor necrosis factor and interleukin-1., Clin. Res., 36, 456
  9. Graybill, 1982, Ketoconazole therapy for systemic fungal infections: Inadequacy of standard dose regimens., Am. Rev. Respir. Dis., 126, 171
  10. Gupta, 1994, Antifungal agents: An overview. Part II., J. Am. Acad. Dermatol., 30, 911, 10.1016/S0190-9622(94)70112-1 · DOI
  11. Hiemenz, 1995, Emergency use of amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis historical control comparison with amphotericin B, Blood, 86, 849a
  12. Jolidon, 1993, 2,3 oxidosqualene-lanosterol cyclase, an attractive target for antifungal drug design.
  13. Moore, 1995, Hematopoietic reconstitution: New approaches., Clin. Cancer Res., 1, 3
  14. Peeters, 1986, Itraconzole, a new orally active triazole derivative for treatment of vaginal candidosis., Curr. Ther. Res., 39, 496
  15. Plempel, 1988, Antimycotic effects of BAY R 3783 in vitro and on dermatophytoses and opportunistic mycoses of the organs in vivo, Rev. lb. Micol., 5, 0
  16. Ringden, 1993, Clinical experience with AmBisome with special emphasis on experience with children., Bone Marrow Transplant., 12, S149
  17. Schaude, 1988, Biological activity of SDZ 89485 in animal models., Rev. lb. Micol., 5, P51
  18. Shepard, 1986, Cyclosporin-ketoconazole: A potentially dangerous drug interaction., Clin. Pharmacol., 6, 468

Cited by

Sorted by citations

See all 377

Related

See all

Metadata

Authors
Groll, A. H., Piscitelli, S. C., & Walsh, T. J.
Affiliations
National Institutes of Health (US)
ORCID
Venue
Advances in pharmacology
Publisher
Elsevier
Published
1998
Volume
44
Pages
343-500
ISSN
1054-3589 (ISSN-L)
DOI
10.1016/s1054-3589(08)60129-5
OpenAlex
W63281979
Cited by
377
References
930
Citations by year
2026: 3 · 2025: 3 · 2024: 16 · 2023: 7 · 2022: 12 · 2021: 8 · 2020: 13 · 2019: 7 · 2018: 8 · 2017: 10 · 2016: 13 · 2015: 13 · 2014: 16 · 2013: 13 · 2012: 7
FWCI
54.29
Type
book chapter
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Advances in pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords
systemic antifungal agents, clinical pharmacology, antifungal drug development, antifungal drug targets, fungal infection
MeSH terms
Animals, Antifungal Agents, Fungi, Humans, Mycoses, Triazoles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review